Product Overview

NeoLNP™ Ultra Antibody-Conjugated ctLNP Kit (for Primary Human T Cells) SDR9001 is a ready-to-use lipid nanoparticle suspension designed for efficient RNA transfection in primary human T cells. Leveraging innovative antibody-conjugated cell-targeted lipid nanoparticle (ctLNP) technology, this product facilitates endogenous cellular trafficking in T cells, enabling high-efficiency RNA transfection. Additionally, it employs patented transient and efficient RNA encapsulation technology, allowing the preparation of RNA-ctLNP through simple mixing. The kit is widely applied in immunotherapy research (e.g., CAR-T, TCR-T), tumor immunology, and in vitro T cell function studies.

Product Advantages

• • Antibody-conjugated cell-targeted lipid nanoparticles (ctLNP): A "smart key" to break through cellular barriers;

• • Patented transient RNA encapsulation technology: RNA-ctLNP preparation via simple mixing;

• • Compatible with common nucleic acid types: mRNA, sgRNA, siRNA, etc.;

• • Biodegradable with extremely low cytotoxicity, maintaining high T cell viability.

Transfection Efficiency of ≥85% for mRNA in Primary Human T Cells

On day 3 after activating primary human T cells with CD3/CD28 magnetic beads, EGFP mRNA was transfected using SDR9001. At 24 hours post-transfection, qualitative evaluation of EGFP protein expression, cell morphology, and viability was performed via fluorescence microscopy. Results showed that over 87% of cells expressed GFP protein at 24 hours post-transfection.

Figure 1. Fluorescence microscopy images of EGFP mRNA transfection in primary human T cells using NeoLNP™ Ultra SDR9001 (48-well plate, EGFP mRNA 400ng/well).

Figure 2. Flow cytometry results of EGFP mRNA transfection in primary human T cells using NeoLNP™ Ultra SDR9001 (total T cells).

Figure 3. Flow cytometry results of EGFP mRNA transfection in primary human T cells using NeoLNP™ Ultra SDR9001 (CD3+, CD4+, CD8+ subsets).

High Cellular Endocytosis Efficiency

On day 3 after activating primary human T cells, Cy3-siRNA was transfected using NeoLNP™ Ultra SDR9001. At 6 hours post-transfection, qualitative evaluation of siRNA distribution, cell morphology, and viability was conducted via fluorescence microscopy. Results demonstrated that SDR9001 achieves efficient transfection of Cy3-siRNA in primary human T cells.

Figure 4. Fluorescence microscopy images of Cy3-siRNA transfection in primary human T cells (48-well plate, Cy3-siRNA 400ng/well).

Maintenance of High T Cell Viability

Transfection of primary human T cells with NeoLNP™ Ultra enables high-efficiency RNA delivery while maintaining a relative viability of over 90% in activated primary human T cells. NeoLNP™ Ultra has minimal impact on T cell proliferation.

Figure 5. T cell viability at 24h and 48h post-EGFP mRNA transfection measured by flow cytometry.

NeoLNP™ Ultra Antibody-Conjugated ctLNP Delivery Technology: Simplifying Primary Immune Cell Transfection

The NeoLNP™ Ultra Transfection Kit integrates antibody-conjugated cell-targeted delivery technology with an innovative high-efficiency RNA-ctLNP encapsulation protocol. Compared to traditional methods, NeoLNP™ eliminates the need for complex equipment – RNA can be encapsulated with zero loss through simple mixing, significantly reducing RNA-ctLNP preparation time. This technology successfully overcomes the high technical barriers of conventional LNP preparation, making meticulously optimized targeted ctLNP accessible to every researcher and offering a new experience for RNA transfection in primary T cells.

Flexible Business Models

To accelerate your research progress, Scindypharm offers flexible NeoLNP™ licensing models tailored to your therapeutic application needs, along with scalable solutions aligned with drug development stages. Our comprehensive delivery portfolio includes NeoLNP™ transfection reagents and i-Core LNP™ delivery solutions. For custom product or service requirements, please contact us.

i-Core LNP™ Delivery Solutions

• •  CAR antibody-conjugated tLNP delivery solutions

• •  Lung-targeted RNA-LNP delivery solutions

• •  Skin-targeted RNA-LNP delivery solutions

• •  RNA-LNP delivery solutions for vaccines

The NeoLNP™ family continues to expand – the new antibody-conjugated ctLNP creates the strongest combination for immune cell transfection!

Tel: +86-512-88865668

Official Website: www.scindypharm.com

Scan the QR code below to submit your requirement information for a chance to win a NeoLNP™ Ultra sample trial.